Company intelligence / Profile preview

AirSeal CardioVascular

Ownership: Private
Development stage: Commercial

Overview

AirSeal CardioVascular has developed and clinically validated a patented, serum-based immunoassay for the diagnosis of peripheral artery disease and other cardiovascular conditions. The cFAS biomarker assay demonstrated high accuracy in over 500 patients across three independent clinical trials, with results published or pending publication in peer-reviewed journals.

Therapeutic areas: Cardiovascular
Modalities: DeviceImmunoassayBiomarker-based diagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

PADGuard

Commercial

Indications: Cardiovascular disease

Partnerships

Washington University School of Medicine (discovery and research collaboration on cFAS biomarker)Arch Grants/BioGenerator EIR program support

Beyond the preview

Go deeper on AirSeal CardioVascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AirSeal CardioVascular.

Explore the full profile